Adenovirus as an emerging pathogen in immunocompromised patients

Summary Adenoviruses are non‐enveloped, lytic, DNA viruses capable of infecting most animal species. There are 51 different human adenovirus serotypes, which are grouped from A to F on the basis of genome size, composition, homology and organization. Pathogenicity varies according to group and type,...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of haematology Vol. 128; no. 2; pp. 135 - 144
Main Authors Leen, Ann M., Rooney, Cliona M.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.01.2005
Blackwell
Blackwell Publishing Ltd
Subjects
Adenoviridae - genetics
Adenoviridae Infections - complications
adenovirus
Adoptive Transfer
Antiviral Agents - therapeutic use
Biological and medical sciences
Hematologic and hematopoietic diseases
Hematology
Humans
Immunocompromised Host
immunocompromised patients
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
immunotherapy
Medical sciences
T cells
T-Lymphocytes, Cytotoxic - immunology
Transduction, Genetic - methods
Virus
Human
Adenoviridae
Treatment
Hematology
Immunotherapy
Pathogenic
T-Lymphocyte
adenovirus
immunocompromised patients
T cells
Immune deficiency
Online AccessGet full text

Cover

More Information
Summary:Summary Adenoviruses are non‐enveloped, lytic, DNA viruses capable of infecting most animal species. There are 51 different human adenovirus serotypes, which are grouped from A to F on the basis of genome size, composition, homology and organization. Pathogenicity varies according to group and type, but infections are generally well controlled by the host immune system in immunocompetent individuals. However, in the immunosuppressed, adenoviral infections are a frequent cause of morbidity and mortality. To date there is no effective therapy. Adoptive transfer of immune T cells offers a therapeutic option, but this strategy has been hindered by the lack of information on targets of protective cellular immunity, and by the immunological heterogeneity of the 51 human adenoviruses. Nevertheless, until such an approach is implemented, or an effective antiviral agent becomes commercially available, it is likely that adenovirus infections will continue to be responsible for a significant number of virus‐associated deaths each year.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2004.05218.x